At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
GW642444 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-wk Study to Evaluate the Safety, Tolerability,Pharmacodynamics and Pharmacokinetics of GW642444H(100 Administered Once Daily in the Morning Via DISKUS™ Dry-powder Inhaler)Compared With SEREVENT(Salmeterol)(50mcg Administered Twice Daily Via DISKUS Dry-powder Inhaler)and Placebo in Subject w/COPD
In Brief
A Phase 2 clinical trial evaluating GW642444 and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 68 participants across 14 sites in 6 countries.
Detailed Summary
The compound GW642444 has previously been found to be well tolerated with no significant side effects in subjects with asthma and healthy volunteers. This study will assess the safety and tolerability of GW642444 in subjects with COPD in order to obtain information to support dosing in a broader population of subjects with COPD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesAustralia, Bulgaria, Germany, Netherlands, New Zealand, Romania
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartNov 2006
Primary CompletionMay 2007
Study CompletionMay 2007
TodayJul 2026
First PostedSep 6, 2006
Enrollment StartNov 3, 2006
Primary CompletionMay 1, 2007
Study CompletionMay 10, 2007
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 19.8 years ago
Interventions
GW642444drug
GW642444H
Placeboother
Placebo administered twice daily